Myovant Sciences (MYOV) Rating Increased to Overweight at Barclays

Myovant Sciences (NYSE:MYOV) was upgraded by investment analysts at Barclays from an “equal weight” rating to an “overweight” rating in a report released on Wednesday, The Fly reports.

Other equities analysts also recently issued research reports about the company. Citigroup dropped their price target on Myovant Sciences from $44.00 to $42.00 and set a “buy” rating on the stock in a research report on Monday, November 19th. Cowen reiterated a “buy” rating on shares of Myovant Sciences in a research note on Friday, November 9th. ValuEngine upgraded Myovant Sciences from a “hold” rating to a “buy” rating in a research note on Monday, January 7th. JMP Securities restated a “buy” rating and issued a $25.00 price objective on shares of Myovant Sciences in a research note on Monday. Finally, Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $29.80.

NYSE MYOV opened at $19.19 on Wednesday. The company has a market cap of $1.31 billion, a PE ratio of -7.96 and a beta of 0.68. The company has a debt-to-equity ratio of 2.08, a quick ratio of 3.51 and a current ratio of 3.51. Myovant Sciences has a fifty-two week low of $13.13 and a fifty-two week high of $27.45.

Myovant Sciences (NYSE:MYOV) last released its earnings results on Thursday, February 7th. The company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.06). On average, equities analysts expect that Myovant Sciences will post -4 earnings per share for the current year.

In related news, Director Mark Altmeyer bought 3,500 shares of the company’s stock in a transaction that occurred on Saturday, November 17th. The shares were purchased at an average cost of $13.38 per share, with a total value of $46,830.00. Following the completion of the acquisition, the director now directly owns 3,500 shares in the company, valued at $46,830. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Opera Trading Capital acquired a new stake in Myovant Sciences during the third quarter worth about $117,000. Atria Investments LLC acquired a new stake in Myovant Sciences during the third quarter worth about $201,000. Renaissance Technologies LLC acquired a new stake in Myovant Sciences during the second quarter worth about $297,000. First Manhattan Co. acquired a new stake in Myovant Sciences during the fourth quarter worth about $292,000. Finally, BlackRock Inc. grew its holdings in Myovant Sciences by 5.2% in the fourth quarter. BlackRock Inc. now owns 27,912 shares of the company’s stock valued at $458,000 after purchasing an additional 1,386 shares during the period. 25.86% of the stock is currently owned by hedge funds and other institutional investors.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

See Also: What is a back-end load?

The Fly

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.